Literature DB >> 25041904

LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions.

Donald G Mitchell1, Jordi Bruix, Morris Sherman, Claude B Sirlin.   

Abstract

To improve standardization and consensus regarding performance, interpreting, and reporting computed tomography (CT) and magnetic resonance imaging (MRI) examinations of the liver in patients at risk for hepatocellular carcinoma (HCC), LI-RADS (Liver Imaging Reporting and Data System) was launched in March 2011 and adopted by many clinical practices throughout the world. LI-RADS categorizes nodules recognized at CT or MRI, in patients at high risk of HCC, as definitively benign, probably benign, intermediate probability of being HCC, probably HCC, and definitively HCC (corresponding to LI-RADS categories 1-5). The LI-RADS Management Working Group, consisting of internationally recognized medical and surgical experts on HCC management, as well as radiologists involved in the development of LI-RADS, was convened to evaluate management implications related to radiological categorization of the estimated probability that a lesion will be ultimately diagnosed as HCC. In this commentary, we briefly review LI-RADS and the initial consensus of the LI-RADS Management Working Group reached during its deliberations in 2013. We then focus on initial discordance of LI-RADS with American Association for the Study of Liver Diseases and Organ Procurement Transplant Network guidelines, the basis for these differences, and how they are being addressed going forward to optimize reporting of CT and MRI findings in patients at risk for HCC and to increase consensus throughout the international community of physicians involved in the diagnosis and treatment of HCC.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 25041904     DOI: 10.1002/hep.27304

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  130 in total

1.  Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations.

Authors:  Cheng William Hong; Charlie C Park; Adrija Mamidipalli; Jonathan C Hooker; Soudabeh Fazeli Dehkordy; Saya Igarashi; Mohanad Alhumayed; Yuko Kono; Rohit Loomba; Tanya Wolfson; Anthony Gamst; Paul Murphy; Claude B Sirlin
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

2.  Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.

Authors:  Mishal Mendiratta-Lala; William Masch; Prasad R Shankar; Holly E Hartman; Matthew S Davenport; Matthew J Schipper; Chris Maurino; Kyle C Cuneo; Theodore S Lawrence; Dawn Owen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-09-10       Impact factor: 7.038

3.  Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy.

Authors:  Nicholas R Perkons; Ryan M Kiefer; Michael C Noji; Mehrdad Pourfathi; Daniel Ackerman; Sarmad Siddiqui; David Tischfield; Enri Profka; Omar Johnson; Stephen Pickup; Anthony Mancuso; Austin Pantel; Michelle R Denburg; Gregory J Nadolski; Stephen J Hunt; Emma E Furth; Stephen Kadlecek; Terence P F Gade
Journal:  Hepatology       Date:  2020-05-16       Impact factor: 17.425

4.  Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.

Authors:  Sun Kyung Jeon; Ijin Joo; Dong Ho Lee; Sang Min Lee; Hyo-Jin Kang; Kyoung-Bun Lee; Jeong Min Lee
Journal:  Eur Radiol       Date:  2018-06-28       Impact factor: 5.315

5.  Modified CAIPIRINHA-VIBE without view-sharing on gadoxetic acid-enhanced multi-arterial phase MR imaging for diagnosing hepatocellular carcinoma: comparison with the CAIPIRINHA-Dixon-TWIST-VIBE.

Authors:  Seung Baek Hong; Nam Kyung Lee; Suk Kim; Hyeong Il Seo; Hyun Sung Kim; Dong Uk Kim; Tae Un Kim; Hwa Seong Ryu
Journal:  Eur Radiol       Date:  2019-04-16       Impact factor: 5.315

6.  Use of the Liver Imaging Reporting and Data System in Hepatocellular Carcinoma.

Authors:  Claude Sirlin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-06

7.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

8.  Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs.

Authors:  Christopher G Roth; Dina Halegoua-De Marzio; Flavius F Guglielmo
Journal:  Dig Dis Sci       Date:  2018-05       Impact factor: 3.199

9.  LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?

Authors:  Seung Soo Kim; Jeong Ah Hwang; Hyeong Cheol Shin; Seo-Youn Choi; Tae Wook Kang; Sung Shick Jou; Woong Hee Lee; Suyeon Park; Nam Hun Heo
Journal:  Eur Radiol       Date:  2018-08-02       Impact factor: 5.315

10.  Evaluation of Transient Motion During Gadoxetic Acid-Enhanced Multiphasic Liver Magnetic Resonance Imaging Using Free-Breathing Golden-Angle Radial Sparse Parallel Magnetic Resonance Imaging.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Robert Grimm; Kai Tobias Block; Hersh Chandarana; Berthold Kiefer; Yohan Son
Journal:  Invest Radiol       Date:  2018-01       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.